

**AB 2760- Information Sheet: Medication to reverse Opioid depression.**

California Health & Wellness Plan (CHWP) is advising that, effective January 1, 2019, pursuant to Assembly Bill (AB) 2760, Section 2, § 740-742, prescribers must offer naloxone hydrochloride (HCl), or similar U.S. Food and Drug Administration (FDA)-approved medication, for the partial or complete reversal of opioid depression to patients when certain conditions are present. Further requirements include educating patients about overdose prevention and how to use naloxone HCl, or similar medication, prescribed to help reverse opioid dependency.

- A prescriber is a person licensed, certified, registered, or otherwise authorized to prescribe prescription medications.

**QUALIFYING CONDITIONS**

A prescription for naloxone HCl, or similar medication, should be offered when any of the following apply:

- Patient is receiving 90 or more morphine milligram equivalents of an opioid medication per day.
- Benzodiazepine is prescribed concurrently with an opioid medication.
- Patient has an increased risk for overdose, including a history of overdose, history of substance use disorder, or at high risk of returning to a high dose of opioid medication.

I have been educated regarding overdose prevention and the use of the medication for the complete or partial reversal of opioid depression.

I have read the above and have been offered the option of having naloxone hydrochloride (HCl) or similar medication. I understand that this medication is not covered by hospice.

At this time, I am declining the option of ordering this medication. I understand that I can change my mind at any time and request this medication.

---

Signature \_\_\_\_\_ Date \_\_\_\_\_

---

Patient Name \_\_\_\_\_ Date of Birth \_\_\_\_\_